Serum levels of interleukin-6 are elevated in patients with Parkinson's disease and correlate with physical performance
Open accessAbstract
Some studies have demonstrated altered circulating levels of cytokines, including IL-6, in Parkinson's disease (PD), implying a possible involvement of inflammatory and immune-mediated mechanisms in its pathogenesis. Moreover, the increased production of inflammatory cytokines has been associated with cognitive impairment and poor physical performance in the elderly. We compared serum levels of IL-6 in 44 PD patients and 22 healthy subjects, and correlated them with PD specific instruments and functional tests. Serum levels of IL-6 were significantly increased in PD (p=0.015). There was no correlation between serum levels of IL-6 and instruments traditionally used to assess PD severity. However, we found that PD patients with higher serum levels of IL-6 spent more time at functional mobility tests and had lower gait speed. Also, these patients had major problems to keep balance during functional tasks that required postural changes and that had a reduced base support. These results showed that high levels of IL-6 can be involved with an acceleration of muscle catabolism leading to sarcopenia, therefore contributing to weakness and fatigue, and may also be associated with functional disability in PD.
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
IL-6 levels are elevated in PD patients' serum.
“Increased levels of IL-6 in PD patients’ serum have been reported in a number of studies [254,255,256]”
From Ageing, Cellular Senescence and Neurodegenerative Disease (2018) · cites this paper as [256]
IL-6 originates in skeletal muscle.
“Specifically, IL-6, which originates in skeletal muscle, has been shown with exercise to elicit an anti-inflammatory response that includes elevated expression of a number of factors including IL-10 and IL-1RA, and as well as inhibition of factors like tumor necrosis factor alpha (TNF-alpha).113–115”
From Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease (2013) · cites this paper as [115]
In the context of exercise, IL-6 may play an anti-inflammatory role.
“In addition, the cytokine IL-6, while generally considered a pro-inflammatory marker in PD that correlates with functional impairment (decreased walking speed), may in the context of exercise, play an anti-inflammatory role.”
From Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease (2013) · cites this paper as [115]
Exercise-induced IL-6 elicits an anti-inflammatory response including elevated expression of IL-10 and IL-1RA and inhibition of TNF-alpha.
“Specifically, IL-6, which originates in skeletal muscle, has been shown with exercise to elicit an anti-inflammatory response that includes elevated expression of a number of factors including IL-10 and IL-1RA, and as well as inhibition of factors like tumor necrosis factor alpha (TNF-alpha).113–115”
From Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease (2013) · cites this paper as [115]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Cites
Parkinsonism: onset, progression, and mortality
Hoehn, M. M., & Yahr, M. D. (1967) · Neurology · doi:10.1212/wnl.17.5.427 · Cited by 12,107 · see citing works
Principles of interleukin (IL)-6-type cytokine signalling and its regulation
HEINRICH, P. C., BEHRMANN, I., HAAN, S., HERMANNS, H. M., MÜLLER-NEWEN, G., & SCHAPER, F. (2003) · Biochemical Journal · doi:10.1042/bj20030407 · Cited by 3,272 · see citing works
Brodacki, B., Staszewski, J., Toczyłowska, B., Kozłowska, E., Drela, N., Chalimoniuk, M., & Stępien, A. (2008) · Neuroscience Letters · doi:10.1016/j.neulet.2008.06.040 · Cited by 316 · see citing works
Flagged first, then by citations
Research works printed but not linked: 3
- F.M. Coelho, F.M. Narciso, D.M. Oliveira, D.S. Pereira, A.L. Teixeira, M.M. Teixeira, D.G. Souza, L.S Pereira. sTNFR-1 is an early inflammatory marker in community versus institutionalized elderly women. Inflamm Res. 2009 Aug 22. [Epub ahead of print] PMID: 19701605.
- S. Fahn, R. Elton, Unified Parkinson's disease rating scale, in: S. Fahn, C.d. Marsden, D.b. Caine, M. Goldstein (Eds.), Recent Developments in Parkinson's Disease, vol. 2, Macmillan Health Care information, Florham Park, 1987, pp. 153-163, 293-304.
- B.K. Schilling, R.E Karlage, M.S. Ledoux, R.F. Pfeiffer, L.W. Weiss, M.J. Falvo, Impaired leg extensor strength in individuals with Parkinson disease and relat- edness to functional mobility. Parkinsonism Relat Disord. 2009 Jun 25. [Epub ahead of print] PMID: 19560392.
Cited by
Sorted by citations
Exercise-enhanced neuroplasticity targeting motor and cognitive circuitry in Parkinson's disease
Petzinger, G. M., Fisher, B. E., McEwen, S., Beeler, J. A., Walsh, J. P., & Jakowec, M. W. (2013) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70123-6 · Cited by 798 · see citing works
Chinta, S. J., Woods, G., Demaria, M., Rane, A., Zou, Y., McQuade, A., Rajagopalan, S., Limbad, C., Madden, D. T., Campisi, J., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.092 · Cited by 530 · see citing works
Ageing, Cellular Senescence and Neurodegenerative Disease
Kritsilis, M., V. Rizou, S., Koutsoudaki, P. N., Evangelou, K., Gorgoulis, V. G., & Papadopoulos, D. (2018) · International Journal of Molecular Sciences · doi:10.3390/ijms19102937 · Cited by 448 · see citing works
Czarny, P., Wigner, P., Galecki, P., & Sliwinski, T. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2017.06.036 · Cited by 310 · see citing works
Lindqvist, D., Kaufman, E., Brundin, L., Hall, S., Surova, Y., & Hansson, O. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047387 · Cited by 236 · see citing works
Inflammation is genetically implicated in Parkinson’s disease
Dzamko, N., Geczy, C. L., & Halliday, G. M. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2014.10.028 · Cited by 222 · see citing works
Alrafiah, A., Al-Ofi, E., Obaid, M. T., Alsomali, N., & Muthuraju, S. (2019) · BioMed Research International · doi:10.1155/2019/2690205 · Cited by 27 · see citing works
Clinical Phenotype of Depression Affects Interleukin-6 Synthesis
Zadka, Ł., Dzięgiel, P., Kulus, M., & Olajossy, M. (2017) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2016.0074 · Cited by 20 · see citing works
Jiao, L., Du, X., Jia, F., Li, Y., Zhu, D., Tang, T., Jiao, Q., & Jiang, H. (2021) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2021.01.011 · Cited by 19 · see citing works
- Authors
- Scalzo, P., Kümmer, A., Cardoso, F., & Teixeira, A. L.
- Affiliations
- Universidade Federal de Minas Gerais (BR)
- Corresponding author
- Teixeira, Antônio Lúcio
- Venue
- Neuroscience Letters
- Publisher
- Elsevier BV
- Published
- 2010-01
- Volume
- 468
- Issue
- 1
- Pages
- 56-58
- ISSN
- 0304-3940 (ISSN-L)
- OpenAlex
- W2014761344
- Cited by
- 175
- References
- 3
- Citations by year
- 2026: 6 · 2025: 19 · 2024: 18 · 2023: 13 · 2022: 12 · 2021: 9 · 2020: 12 · 2019: 12 · 2018: 13 · 2017: 10 · 2016: 11 · 2015: 7 · 2014: 13 · 2013: 5 · 2012: 10
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- Neuroscience Letters (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Universidade Federal de Minas Gerais
- Topics
- Health Sciences › Medicine › Neurology › Parkinson's Disease Mechanisms and Treatments
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Health Sciences › Health Professions › Physical Therapy, Sports Therapy and Rehabilitation › Balance, Gait, and Falls Prevention
- Keywords
- Parkinson's disease, interleukin-6, serum cytokines, inflammation, physical performance, walking speed, balance, functional mobility, sarcopenia, muscle catabolism, functional disability, fatigue
- MeSH terms
- Aged, Cognition, Postural Balance, Female, Gait, Humans, Male, Middle Aged, Parkinson Disease, Interleukin-6, Walking
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
